Thursday 16 October, 2025
Introduction Patients with recurrent high-grade glioma (rHGG) have poor prognosis with median progression-free survival (PFS) <6 months, and median overall…
Read morePoster: Drug/Disease Modelling - Oncology
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin
Thursday 16 October, 2025
Objectives: Tisotumab vedotin (TV), a tissue factor-directed antibody-drug conjugate (ADC), is approved in the United States at a dose of 2.0…
Read moreModel informed dosage regimen optimization of anti-CD47 antibody using target-mediated drug disposition model.
Thursday 16 October, 2025
Objectives: Target-mediated drug disposition (TMDD) model is used to describe a nonlinear pharmacokinetics (PK) phenomenon that is caused by high-affinity…
Read moreUncoupling tumor cell killing and cytokine release following T-cell engager administration with a mechanistic PKPD model
Thursday 16 October, 2025
Objectives: T-cell engagers (TCE) are anti-cancer therapeutic agents that reactivate the patient’s immune system. They are promising therapies with remaining…
Read moreA mechanistic PK/PD model to predict cytokine release and tumor cell killing associated to T-cell bispecific therapies
Thursday 16 October, 2025
Objectives: T-cell bispecifics (TCB) are promising anti-tumor therapies with remaining challenges associated with their clinical safety profiles. In particular, Cytokine…
Read morePhysiologically based pharmacokinetic modelling of the PSMA radioligand 18F-DCFPyL to predict the tissue distribution in patients with prostate cancer
Thursday 16 October, 2025
Objectives: The most common malignancy in middle and older aged men worldwide is prostate cancer (PCa).1 Characteristic for PCa is a…
Read moreEnabling Tyrosine Kinase Inhibitor Precision Medicine through PET-Guided Physiologically-Based Pharmacokinetic Modeling
Thursday 16 October, 2025
Objectives: Osimertinib, a tyrosine kinase inhibitor (TKI), is used in treating non-small cell lung cancer (NSCLC) with epidermal growth factor…
Read moreEarly morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study
Thursday 16 October, 2025
Objectives: Anticancer drug administration timing may greatly affect patient’s survival, response and toxicities (1, 2). This time-of-day variability originates from…
Read moreQuantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors.
Thursday 16 October, 2025
Objectives: Large inter-patient heterogeneity in anticancer drug response highlights the critical need for personalized cancer management which has favored the…
Read morePopulation pharmacokinetics of belantamab mafodotin in relapsed or refractory multiple myeloma patients with severe renal impairment
Thursday 16 October, 2025
Objectives: Belantamab mafodotin is an antibody-drug conjugate (ADC) consisting of an afucosylated humanized anti-B‐cell maturation antigen (BCMA) monoclonal antibody (mAb)…
Read more